These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 25140364)
21. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Raghu G Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29074545 [TBL] [Abstract][Full Text] [Related]
22. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. Karimi-Shah BA; Chowdhury BA N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913 [No Abstract] [Full Text] [Related]
24. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Oltmanns U; Kahn N; Palmowski K; Träger A; Wenz H; Heussel CP; Schnabel PA; Puderbach M; Wiebel M; Ehlers-Tenenbaum S; Warth A; Herth FJ; Kreuter M Respiration; 2014; 88(3):199-207. PubMed ID: 25115833 [TBL] [Abstract][Full Text] [Related]
25. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation? Papiris SA; Kagouridis K; Kolilekas L; Triantafillidou C; Tsangaris I; Manali ED Eur Respir J; 2012 Sep; 40(3):794-5. PubMed ID: 22941551 [No Abstract] [Full Text] [Related]
26. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557 [TBL] [Abstract][Full Text] [Related]
27. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic targets in idiopathic pulmonary fibrosis. Kolb M; Bonella F; Wollin L Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042 [TBL] [Abstract][Full Text] [Related]
29. Naloxegol oxalate, pirfenidone, and nintedanib. Hussar DA; Jeon MM J Am Pharm Assoc (2003); 2015; 55(4):461-3. PubMed ID: 26161491 [No Abstract] [Full Text] [Related]
31. [Idiopathic pulmonary fibrosis: A new era, new challenges]. Cottin V Rev Mal Respir; 2014 Sep; 31(7):583-6. PubMed ID: 25239578 [No Abstract] [Full Text] [Related]